Dr. Chien Ting Lin is an M.D. who graduated from National Taiwan University and has been working at Far Eastern Memorial Hospital, Tai-Cheng Stem Cell Therapy Center, and National Taiwan University Hospital. In addition, he has been to the University of Pennsylvania as an international research scholar to do CAR-T research. With more than 15 years of clinical experience, Dr. Lin is familiar with hematological cancer treatment and clinical trial design and execution. As a senior vice president and chief technology officer at PELL, he discovered and validated a novel CAR design in the R&D platform and established CAR-T GTP-grade manufacturing. He also initiated a phase 1/2 CD19 CAR-T clinical trial. Besides, he also won an A+ grant from the Ministry of Economic Affairs. Dr. Lin’s work was recognized with National Innovation Award and International R&D 100 Award. In addition, he is the innovator of several patents.